Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov42610.25208/0042-4609-2018-94-4-68-72DRUG TREATMENT IN DERMATOVENEROLOGYФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИFeatures of treatment of patients with psoriasis with metabolic syndromeОсобенности терапии больных псориазом с метаболическим синдромомKhairutdinovV. R.ХайрутдиновВ. Р.
Russian Federation

Dr. Sci. (Med.), Ass. Prof., Department of Skin and Sexually Transmitted Diseases

Akademika Lebedeva str., 6, Saint Petersburg, 194044, Russian Federation

д.м.н., доцент кафедры кожных и венерических болезней

194044, Российская Федерация, г. Санк т-Петербург, ул. Академика Лебедева, д. 6

haric03@list.ruSamtsovA. V.СамцовА. В.
Russian Federation

Dr. Sci. (Med.), Prof., Departmental Head, Department of Skin and Sexually Transmitted Diseases

Akademika Lebedeva str., 6, Saint Petersburg, 194044, Russian Federation

д.м.н., профессор, заведующий кафедрой кожных и венерических болезней

194044, Российская Федерация, г. Санк т-Петербург, ул. Академика Лебедева, д. 6

avsamtsov@mail.ruS. M. Kirov Militar y Medical AcademyВоенно-медицинская академия им. С. М. Кирова Министерства обороны Российской Федерации0708201894468720712201807122018Copyright ©; 2018, Khairutdinov V.R., Samtsov A.V.Copyright ©; 2018, Хайрутдинов В.Р., Самцов А.В.2018Khairutdinov V.R., Samtsov A.V.Хайрутдинов В.Р., Самцов А.В.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/426

The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Systemic subclinical inflammatory process developing in psoriasis and metabolic syndrome is considered as the main pathogenetic mechanism of their mutual negative influence. The difficulties of treatment of patients with psoriasis with metabolic syndrome are largely associated with the choice of a safe and effective method of treatment. The description of the drug apremilast (OTEZLA®) is a selective inhibitor of the enzyme phosphodiesterase 4, which may be the best drug in the therapy of patients with psoriasis and metabolic syndrome.

В статье приведены сведения о распространенности метаболического синдрома у больных псориазом. Представлены критерии диагностики метаболического синдрома. Описаны общие механизмы развития воспаления при псориазе и заболеваниях, формирующих метаболический синдром. Системный субклинический воспалительный процесс, развивающийся при псориазе и метаболическом синдроме, рассматривается как основной патогенетический механизм их взаимного негативного влияния. Трудности терапии больных псориазом с метаболическим синдромом во многом связаны с выбором безопасного и эффективного метода лечения. Приведено описание препарата апремиласта (ОТЕСЛА®) — селективного ингибитора фермента фософодиэстеразы 4, который может быть оптимальным лекарственным средством в терапии пациентов с псориазом и сопутствующим метаболическим синдромом.

psoriasismetabolic syndromesystemic inflammationapremilastOTEZLAпсориазметаболический синдромсистемное воспалениеапремиластОТЕСЛА1. Michalek I. M., Loring B., John S. M. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205–212. ü2. Rodríguez-Zúñiga M. J. M., García-Perdomo H. A. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017 Oct;77(4):657–666.e8.3. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2006;106(25):3143–3421.5. Sanz L. P. Psoriasis, a systemic disease?. Actas Dermosifiliogr. 2007;98:396–402.6. Machado-Pinto J., Diniz Mdos S., Bavoso N. C. Psoriasis: new comorbidities. An Bras Dermatol. 2016 Jan-Feb;91(1):8–14.7. Takeshita J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377–390.8. Mozos I., Malainer C., Horbańczuk J. et al. Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. Front Immunol. 2017 Aug 31;8:1058.9. Cotie L. M., Currie K. D., McGill G. M. et al. Associations between measures of vascular structure and function and systemic circulating blood markers in humans. Physiol Rep. 2016 Sep;4(18):e12982.10. Woth K., Prein C., Steinhorst K. et al. Endothelial cells are highly heterogeneous at the level of cytokine-induced insulin resistance. Exp Dermatol. 2013 Nov;22(11):714–718.11. Robati R. M., Partovi-Kia M., Haghighatkhah H. R., Younespour S., Abdollahimajd F. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis?. J Am Acad Dermatol. 2014;71:642–648.12. Gerdes S., Rostami-Yazdi M., Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011 Feb;20(2):81–87.13. Armstrong A. W., Voyles S. V., Armstrong E. J., Fuller E. N., Rutledge J. C. A tale of two plaques: convergent mechanisms of T-cellmediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011 Jul;20(7):544–549.14. Carrascosa J. M., van Doorn M. B., Lahfa M. et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1424–1430.15. Инструкция по медицинскому применению препарата ацитретин. 2011. [Instructions for Medical Use of the Atsitretin. 2011. (In Russ.)]16. Инструкция по медицинскому применению препарата метотрексат. 2015. [Instructions for Medical Use of the Methotrexate. 2015. (In Russ.)]17. Инструкция по медицинскому применению препарата циклоспорин. 2015. [Instructions for Medical Use of the Ciclosporin. 2015. (In Russ.)]18. Bhole V. M., Choi H. K., Burns L. C. et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012 Mar;51(3):552–556.19. Singh S., Facciorusso A., Singh A. G. et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123.20. Tan E., Baker C., Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol. 2013 Nov;54(4):259–263.21. Gisondi P., Del Giglio M., Girolomoni G. Considerations for Systemic Treatment of Psoriasis in Obese Patients. Am J Clin Dermatol. 2016 Dec;17(6):609–615.22. Cao S., Zhang X., Edwards J. P., Mosser D. M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem. 2006 Sep 8;281(36):26041–26050.23. Zhang R., Maratos-Flier E., Flier J. S. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology. 2009 Jul;150(7):3076–3082.24. Yu X. H., Fu Y. C., Zhang D. W. et al. Foam cells in atherosclerosis. Clin Chim Acta. 2013 Sep 23;424:245–252.25. Liu H., Wilder T., Mediero A. et al. Apremilast may improve atherosclerosis by promoting cholesterol efflux and inhibiting foam cell formation in atherosclerotic plaques. Arthritis Rheumatol. 2016;68(suppl 10).26. Torres T., Puig L. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol. 2018 Feb;19(1):23–32. DOI: 10.1007/s40257-017-0302-027. Crowley J., Thaçi D., Joly P. et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017 Aug;77(2):310–317.e1.28. Инструкция по медицинскому применению препарата ОТЕСЛА®. 2017. [Instructions for Medical Use of the OTEZLA®. 2017. (In Russ.)]